scholarly journals Emerging methods in biomarker identification for extracellular vesicle‐based liquid biopsy

2021 ◽  
Vol 10 (7) ◽  
Author(s):  
Yaxuan Liang ◽  
Brandon M. Lehrich ◽  
Siyang Zheng ◽  
Mengrou Lu
Author(s):  
Dan Li ◽  
Wenjia Lai ◽  
Di Fan ◽  
Qiaojun Fang

Breast cancer is the most common malignant disease in women worldwide. Early diagnosis and treatment can greatly improve the management of breast cancer. Liquid biopsies are becoming convenient detection methods for diagnosing and monitoring breast cancer due to their non-invasiveness and ability to provide real-time feedback. A range of liquid biopsy markers, including circulating tumor proteins, circulating tumor cells, and circulating tumor nucleic acids, have been implemented for breast cancer diagnosis and prognosis, with each having its own advantages and limitations. Circulating extracellular vesicles are messengers of intercellular communication that are packed with information from mother cells and are found in a wide variety of bodily fluids; thus, they are emerging as ideal candidates for liquid biopsy biomarkers. In this review, we summarize extracellular vesicle protein markers that can be potentially used for the early diagnosis and prognosis of breast cancer or determining its specific subtypes.


2020 ◽  
Author(s):  
T.A. Hartjes ◽  
J.A. Slotman ◽  
M.S. Vredenbregt ◽  
N. Dits ◽  
R. Van der Meel ◽  
...  

AbstractExtracellular vesicles (EVs) reflect the cell of origin in terms of nucleic acids and protein content. They are found in biofluids and represent an ideal liquid biopsy biomarker source for many diseases. Unfortunately, clinical implementation is limited by available technologies for EV analysis. We have developed a simple, robust and sensitive microscopy-based high-throughput assay (EVQuant) to overcome these limitations and allow widespread use in the EV community. The EVQuant assay can detect individual immobilized EVs as small as 35 nm and determine their concentration in biofluids without extensive EV isolation or purification procedures. It can also identify specific EV subpopulations based on combinations of biomarkers and is used here to identify prostate-derived urinary EVs as CD9-/CD63+. Moreover, characterization of individual EVs allows analysis of their size distribution. The ability to identify, quantify and characterize EV (sub-)populations in high-throughput substantially extents the applicability of the EVQuant assay over most current EV quantification assays.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Diego de Miguel Pérez ◽  
Alba Rodriguez Martínez ◽  
Alba Ortigosa Palomo ◽  
Mayte Delgado Ureña ◽  
Jose Luis Garcia Puche ◽  
...  

2020 ◽  
Author(s):  
Siyang Zheng ◽  
Hongzhang He ◽  
Faming Wang ◽  
Yuan Wan

2020 ◽  
Vol 54 (6) ◽  
pp. 453-461 ◽  
Author(s):  
In Ae Kim ◽  
Jae Young Hur ◽  
Hee Joung Kim ◽  
Seung Eun Lee ◽  
Wan Seop Kim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document